Skip to main content
The Egyptian Journal of Internal Medicine
Download PDF
  • Original article
  • Open access
  • Published:

Fecal B-cell-activating factor as a new noninvasive marker in the evaluation of ulcerative colitis Egyptian patients: a comparative cross-sectional study

The Egyptian Journal of Internal Medicine volume 31, pages 563–572 (2019)Cite this article

Abstract

Background and aim

Diagnosis of ulcerative colitis (UC) is suspected clinically and confirmed through endoscopic biopsy. It can be followed-up and assessed by noninvasive biomarkers such as fecal calprotectin. Recently, B-cell-activating factor (BAFF) has been proposed to be a regulator of B-cell and T-cell immune responses and to be associated with inflammatory processes in autoimmunity. The aim of our study was to clarify the role of fecal BAFF as a simple predictor for disease activity and severity in patients with UC.

Patients and methods

Fifty Egyptian patients with UC were divided into two groups: group I including 40 patients with active UC (newly diagnosed) and group II including 10 patients with inactive UC (previously diagnosed); disease activity was assessed according to the Mayo activity scoring index; fecal BAFF and fecal calprotectin were measured for all patients using enzyme-linked immunosorbent assay.

Results

Significantly higher levels of Fecal BAFF and fecal calprotectin were found among patients with active UC, as compared with inactive UC patients. Fecal BAFF more than or equal to 50 μg/g had 97.5% sensitivity and 100% specificity in predicting disease activity in comparison with fecal calprotectin, which had a sensitivity and specificity of 90% at a cut off value more than or equal to 47 μg/g. In predicting disease severity, fecal BAFF more than or equal to 340 μg/g had a sensitivity of 95% and specificity of 100%, while fecal calprotectin more than or equal to 170 μg/g had a sensitivity of 80% and specificity of 95%.

Conclusion

Fecal BAFF is more sensitive and specific in predicting UC activity and severity than fecal calprotectin.

References

  1. Cakal B, Akoz AG, Ustundag Y, Yalinkilic M, Ulker A, Ankarali H. Red cell distribution width for assessment of activity of inflammatory bowel disease. Dig Dis Sci 2009; 54:842–847.

    Article  Google Scholar 

  2. Yüksel O, Helvaci K, Basar O, Köklü S, Caner S, Helvaci N, et al. An overlooked indicator of disease activity in ulcerative colitis: mean platelet volume. Platelets 2009; 20:277–281.

    Article  Google Scholar 

  3. Krumbholz M, Theil D, Derfuss T, Rosenwald A, Schrader F, Monoranu CM, et al. BAFF is produced by astrocytes and up-regulated in multiple sclerosis lesions and primary central nervous system lymphoma. J Exp Med 2005; 201:195–200.

    Article  CAS  Google Scholar 

  4. Lester SE, Proudman SM, Lee AT, Hall CA, McWilliams L, James MJ, et al. Treatment-induced stable, moderate reduction in blood cell counts correlate to disease control in early rheumatoid arthritis. Intern Med J 2009; 39:296–303.

    Article  CAS  Google Scholar 

  5. Schroeder KW, Tremaine WJ, Ilstrup DM. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomized study. N Engl J Med 1987; 317:1625–1629.

    Article  CAS  Google Scholar 

  6. D’Haens G, Geboes K, Peeters M, Baert F, Ectors N, Rutgeerts P. Patchy cecal inflammation associated with distal ulcerative colitis: a prospective endoscopic study. Am J Gastroenterol 1997; 92:1275–1279.

    PubMed  Google Scholar 

  7. Uzzan M, Colombel JF, Cerutti A, Treton X, Mehandru S. B-cell-activating factor (BAFF)-targeted B cell therapies in inflammatory bowel diseases. Dig Dis Sci 2016; 61:3407–3424.

    Article  CAS  Google Scholar 

  8. Bechtold ML, Choudhary A. Bowel preparation prior to colonoscopy:a continual search for excellence. World J Gastroenterol 2013; 19:155–157.

    Article  Google Scholar 

  9. Smith LA, Gaya DR. Utility of faecal calprotectin analysis in adult inflammatory bowel disease. World J Gastroenterol 2012; 18:6782–6789.

    Article  CAS  Google Scholar 

  10. Striz IB. Cell-activating factor (BAFF) in inflammatory bowel disease: BAFFling no longer? Dig Dis Sci 2016; 61:2456–2458.

    Article  Google Scholar 

  11. Schoepfer AM, Trummler M, Seeholzer P, Seibold-Schmid B, Seibold F. Discriminating IBD from IBS: comparison of the test performance of fecal markers, blood leukocytes, CRP, and IBD antibodies. Inflamm Bowel Dis 2008; 14:32–39.

    Article  Google Scholar 

  12. Paduchova Z, Durackova Z. Fecal calprotectin as a promising marker of inflammatory diseases. Bratisl Lek Listy 2009; 10:598–602.

    Google Scholar 

  13. Zahedi MJ, Darvish Moghadam S, Hayat Bakhsh Abbasi M, Dehghani M, Shafiei Pour S, Zydabady Nejad H, et al. The incidence rate of inflammatory bowel disease in an urban area of Iran: a developing country. Middle East J Dig Dis 2014; 6:32–36.

    PubMed  PubMed Central  Google Scholar 

  14. Tall AR. C-reactive protein reassessed. N Engl J Med 2004; 350:1450–1452.

    Article  CAS  Google Scholar 

  15. Gabay C, Kushner I. Acute-phase proteins and other systemic responses to inflammation. N Engl J Med 1999; 340:448–454.

    Article  CAS  Google Scholar 

  16. Peyrin-Biroulet L, Standaert-Vitse A, Branche J, Chamaillard M. IBD serological panels: Facts and perspectives. Inflamm Bowel Dis 2007; 13:1561–1566.

    Article  Google Scholar 

  17. Solem CA, Loftus EVJr, Tremaine WJ, Harmsen WS, Zinsmeister AR, Sandborn WJ. Correlation of C-reactive protein with clinical, endoscopic, etiologic, and radiographic activity in inflammatory bowel disease. Inflamm Bowel Dis 2005; 11:707–712.

    Article  Google Scholar 

  18. Thomas RD, Westengard JC, Hay KL, Bull BS. Calibration and validation for erythrocyte sedimentation tests. Role of the International Committee on Standardization in Hematology reference procedure. Arch Pathol Lab Med 1993; 117:719–723.

    CAS  Google Scholar 

  19. Leighton JA, Shen B, Baron TH, Adler DG, Davila R, Egan JV, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 4: 558–565.

    Article  Google Scholar 

  20. Langhorst J, Elsenbruch S, Koelzer J, Rueffer A, Michalsen A, Dobos GJ. Non-invasive markers in the assessment of intestinal inflammation in inflammatory bowel diseases: performance of fecal lactoferrin, calprotectin, and PMN-elastase, CRP, and clinical indices. Am J Gastroenterol 2008; 103:162–169.

    Article  Google Scholar 

  21. Silberer H, Küppers B, Mickisch O, Baniewicz W, Drescher M, Traber L, et al. Fecal leukocyte proteins in inflammatory bowel disease and irritable bowel syndrome. Clin Lab 2005; 51:117–126.

    CAS  PubMed  Google Scholar 

  22. Egea-Valenzuela J, Alberca-de-las-Parras F, CarballoAlvarez F. Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by video capsule endoscopy. Rev Esp Enferm Dig 2015; 107:211–215.

    PubMed  Google Scholar 

  23. Zhang P, Liu X, Guo A, Xiong J, Fu Y, Zou K. B cell-activating factor as a new potential marker in inflammatory bowel disease. Dig Dis Sci 2016; 61:2608–2618.

    Article  CAS  Google Scholar 

  24. Fu Y, Wang L, Xie C, Zou K, Tu L, Yan W, et al. Comparison of non-invasive biomarkers faecal BAFF, calprotectin and FOBT in discriminating IBS from IBD and evaluation of intestinal inflammation. Sci Rep 2017; 7:2669.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Internal Medicine, Gastroenterology and Hepatology Unit, Ain Shams University, Abbasyia Square, Cairo, 11211, Egypt

    Hany A. Hussein (MD Internal Medicine) & Rasha S. Mohamed

Authors
  1. Hany A. Hussein
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Rasha S. Mohamed
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Hany A. Hussein.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hussein, H.A., Mohamed, R.S. Fecal B-cell-activating factor as a new noninvasive marker in the evaluation of ulcerative colitis Egyptian patients: a comparative cross-sectional study. Egypt J Intern Med 31, 563–572 (2019). https://doi.org/10.4103/ejim.ejim_118_19

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejim.ejim_118_19

Keywords